Paid Clinical Trials and Focus Groups by Location |
|
|
|
Condition: Acute Gout
Interventions: Drug: ACZ885; Drug: Triamcinolone acetonide
Sponsor: Novartis Pharmaceuticals
Not yet recruiting - verified March 2010
Condition: Asthma
Interventions: Drug: Indacaterol dose; Drug: Placebo; Drug: Salmeterol
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: Indacaterol; Drug: Placebo
Sponsor: Novartis
Recruiting - verified February 2010
Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: Aclidinium bromide; Drug: Aclidinium bromide; Drug: Placebo
Sponsors: Forest Laboratories; Almirall, S.A.
Recruiting - verified February 2010
Condition: Lung Cancer
Interventions: Biological: Seneca Valley virus-001; Other: placebo
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Liver Cancer
Interventions: Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: mitomycin C; Drug: sorafenib tosylate; Other: placebo
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Genetic: cytogenetic analysis; Genetic: fluorescence in situ hybridization
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI); Eastern Cooperative Oncology Group
Recruiting - verified March 2010
Conditions: Osteoarthritis, Knee; Osteoarthritis, Hip
Interventions: Other: Tanezumab 2.5 mg; Other: Tanezumab 5 mg; Other: Tanezumab 10 mg
Sponsor: Pfizer
Recruiting - verified February 2010
Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Biological: bevacizumab; Biological: cetuximab; Drug: carboplatin; Drug: paclitaxel
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Advanced Non-Small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Carboplatin; Drug: Paclitaxel; Biological: Bevacizumab
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Conditions: Bladder Cancer; Prostate Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: gemcitabine hydrochloride; Drug: placebo administration
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Carcinoma of Unknown Primary
Interventions: Drug: carboplatin; Drug: everolimus; Drug: paclitaxel; Genetic: gene expression analysis; Other: laboratory biomarker analysis
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Precancerous Condition
Intervention: Other: biologic sample preservation procedure
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Intervention: Other: biologic sample preservation procedure
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Cancer; Cataract; Low Bone Mineral Density; Osteopenia; Osteoporosis; Prostate Cancer
Interventions: Biological: Denosumab; Biological: Placebo
Sponsor: Amgen
Recruiting - verified March 2010
Conditions: Atrial Fibrillation; Arrhythmia; Stroke Prevention; Mortality
Interventions: Device: Left atrial ablation; Drug: Rate or Rhythm Control Therapy
Sponsors: Mayo Clinic; National Heart, Lung, and Blood Institute (NHLBI); Duke University; St. Jude Medical; Biosense Webster, Inc.
Recruiting - verified February 2010
Conditions: Anal Cancer; Carcinoma of the Appendix; Colorectal Cancer; Extrahepatic Bile Duct Cancer; Gallbladder Cancer; Gastric Cancer; Gastrointestinal Carcinoid Tumor; Liver Cancer; Nausea and Vomiting; Pancreatic Cancer; Peritoneal Cavity Cancer; Small Intestine Cancer
Interventions: Drug: palonosetron hydrochloride; Other: placebo
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified February 2010
Conditions: Multiple Myeloma and Plasma Cell Neoplasm; Precancerous Condition
Interventions: Genetic: cytogenetic analysis; Genetic: microarray analysis; Other: biologic sample preservation procedure; Other: laboratory biomarker analysis
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lymphoma
Interventions: Other: biologic sample preservation procedure; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lymphoma
Intervention: Other: cryopreservation
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer
Interventions: Drug: capecitabine; Drug: sunitinib malate
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: systemic chemotherapy; Procedure: axillary lymph node dissection; Procedure: neoadjuvant therapy; Procedure: sentinel lymph node biopsy; Procedure: therapeutic conventional surgery; Procedure: ultrasound imaging
Sponsors: American College of Surgeons; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Nausea and Vomiting; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: dexamethasone; Drug: gabapentin; Other: placebo
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Breast Cancer; Lung Cancer; Metastatic Cancer; Multiple Myeloma and Plasma Cell Neoplasm; Prostate Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Procedure: assessment of therapy complications
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: neratinib; Other: placebo
Sponsor: Wyeth
Recruiting - verified March 2010
Conditions: Breast Cancer; Metastatic Cancer; Multiple Myeloma and Plasma Cell Neoplasm; Musculoskeletal Complications; Pain; Prostate Cancer; Urinary Complications
Intervention: Drug: zoledronic acid
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Liver Cancer
Interventions: Biological: bevacizumab; Drug: sorafenib tosylate
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Coronary Artery Bypass; Myocardial Infarction; Ventricular Dysfunction, Left; Stroke; Cardiopulmonary Bypass
Interventions: Drug: Acadesine; Drug: Normal Saline
Sponsor: Schering-Plough
Recruiting - verified March 2010
Conditions: Chemotherapeutic Agent Toxicity; Neurotoxicity; Pain; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: paclitaxel; Genetic: polymorphism analysis; Other: laboratory biomarker analysis; Other: questionnaire administration; Procedure: assessment of therapy complications
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Optic Neuritis
Interventions: Drug: Glatiramer Acetate (Copaxone); Drug: placebo
Sponsor: Teva Pharmaceutical Industries
Recruiting - verified February 2010
Conditions: Anemia; Leukemia; Myelodysplastic Syndromes
Interventions: Biological: epoetin alfa; Drug: lenalidomide
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Drug: cytarabine; Drug: idarubicin; Drug: pravastatin
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Biological: aflibercept; Drug: topotecan hydrochloride
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lymphoma
Interventions: Biological: bleomycin sulfate; Biological: filgrastim; Drug: ABVD regimen; Drug: BEACOPP regimen; Drug: cyclophosphamide; Drug: dacarbazine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: prednisone; Drug: procarbazine hydrochloride; Drug: vinblastine; Drug: vincristine sulfate; Radiation: fludeoxyglucose F 18
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Cervical Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: paclitaxel; Drug: topotecan hydrochloride
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: pemetrexed disodium; Genetic: gene expression analysis; Genetic: polymorphism analysis; Genetic: protein expression analysis; Other: laboratory biomarker analysis; Other: pharmacogenomic studies; Procedure: quality-of-life assessment
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Drug: cisplatin; Drug: gemcitabine hydrochloride; Other: active surveillance
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Extrahepatic Bile Duct Cancer; Gallbladder Cancer
Interventions: Drug: capecitabine; Drug: gemcitabine hydrochloride; Procedure: adjuvant therapy; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lymphoma
Interventions: Biological: rituximab; Drug: cladribine; Drug: temsirolimus; Genetic: cytogenetic analysis; Genetic: gene expression analysis; Genetic: protein expression analysis; Other: laboratory biomarker analysis; Other: liquid chromatography; Other: mass spectrometry
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: ixabepilone; Drug: paclitaxel; Drug: paclitaxel albumin-stabilized nanoparticle formulation
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Other: clinical observation; Radiation: radiation therapy
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Breast Cancer; Chemotherapeutic Agent Toxicity; Fatigue; Neuropathy; Neurotoxicity
Interventions: Dietary Supplement: acetyl-L-carnitine hydrochloride; Other: placebo
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lymphoma
Interventions: Biological: rituximab; Biological: tositumomab; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: prednisone; Drug: vincristine sulfate; Radiation: iodine I 131 tositumomab
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: trastuzumab; Radiation: radiation therapy
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Chronic Myeloproliferative Disorders; Fatigue; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Precancerous Condition; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Dietary Supplement: American ginseng; Other: placebo
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Drug: sunitinib malate; Other: placebo
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: cixutumumab; Drug: capecitabine; Drug: lapatinib ditosylate
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI); Southwest Oncology Group
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Drug: carboplatin; Drug: erlotinib hydrochloride; Drug: paclitaxel
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Drug: azacitidine; Drug: gemtuzumab ozogamicin
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: bortezomib; Drug: dexamethasone; Drug: lenalidomide
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Coronary Heart Disease
Interventions: Drug: dalcetrapib; Drug: Placebo; Drug: Evidence-based medical care for Acute Coronary Syndrome
Sponsor: Hoffmann-La Roche
Recruiting - verified March 2010
Condition: Brain and Central Nervous System Tumors
Interventions: Biological: bevacizumab; Drug: sorafenib tosylate; Other: flow cytometry; Other: immunoenzyme technique; Other: laboratory biomarker analysis; Other: pharmacogenomic studies
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Pancreatic Cancer
Interventions: Biological: cixutumumab; Drug: erlotinib hydrochloride; Drug: gemcitabine hydrochloride
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Hypoactive Sexual Desire Disorder
Interventions: Drug: testosterone gel; Drug: placebo gel
Sponsor: BioSante Pharmaceuticals
Recruiting - verified February 2010
Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: letrozole; Drug: tamoxifen citrate; Other: placebo
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: lenalidomide; Drug: melphalan; Drug: prednisone; Drug: thalidomide
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Pancreatic Cancer
Interventions: Biological: panitumumab; Drug: capecitabine; Drug: fluorouracil; Drug: gemcitabine hydrochloride; Radiation: radiation therapy
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Sepsis
Interventions: Drug: Drotrecogin alfa (activated); Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Condition: Hypoactive Sexual Desire Disorder
Interventions: Drug: testosterone gel; Drug: placebo gel
Sponsor: BioSante Pharmaceuticals
Recruiting - verified February 2010
Condition: Head and Neck Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: docetaxel; Drug: fluorouracil
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Neuroendocrine Carcinoma
Interventions: Biological: bevacizumab; Biological: recombinant interferon alfa-2b; Drug: octreotide acetate
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: thioguanine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; Southwest Oncology Group
Recruiting - verified March 2010
Condition: Venous Thromboembolism
Interventions: Drug: dabigatran etexilate 150 mg BID; Drug: matching placebo BID
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Drug: arsenic trioxide; Drug: gemtuzumab ozogamicin; Drug: mercaptopurine; Drug: methotrexate; Drug: tretinoin
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Pancreatic Cancer
Interventions: Biological: panitumumab; Drug: erlotinib hydrochloride; Drug: gemcitabine hydrochloride
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Prostate Cancer; Breast Cancer; Ovarian Cancer; Lung Cancer; Gastric Cancer
Intervention: Drug: Docetaxel plus lonafarnib
Sponsor: Schering-Plough
Recruiting - verified March 2010
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: bortezomib; Drug: dexamethasone; Drug: lenalidomide
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Parkinson's Disease
Interventions: Drug: Rotigotine; Drug: Rotigotine; Other: Placebo
Sponsor: UCB, Inc.
Recruiting - verified March 2010
Conditions: Staphylococcus Aureus; Bacteremia; Mediastinitis
Interventions: Biological: V710; Biological: Comparator: Placebo (unspecified)
Sponsor: Merck
Recruiting - verified March 2010
Condition: Colorectal Cancer
Interventions: Biological: bevacizumab; Biological: cetuximab; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: leucovorin calcium
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI); North Central Cancer Treatment Group; Cancer and Leukemia Group B; Eastern Cooperative Oncology Group; NCIC Clinical Trials Group
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Drug: mercaptopurine; Drug: methotrexate; Drug: tretinoin; Other: clinical observation
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: Trastuzumab; Drug: Lapatinib
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Lymphoma
Interventions: Biological: denileukin diftitox; Biological: rituximab; Other: flow cytometry; Other: immunoenzyme technique; Other: laboratory biomarker analysis
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Drug: pemetrexed disodium; Drug: sorafenib tosylate
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Genetic: chromogenic in situ hybridization; Genetic: gene expression analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: fluorescent antibody technique; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Other: matrix-assisted laser desorption/ionization time of flight mass spectrometry; Other: study of socioeconomic and demographic variables; Procedure: study of high risk factors
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Biological: bevacizumab; Drug: erlotinib hydrochloride
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Bladder Cancer
Interventions: Drug: gemcitabine hydrochloride; Other: placebo
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Biological: bevacizumab; Drug: erlotinib hydrochloride
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Small Intestine Cancer
Interventions: Drug: capecitabine; Drug: irinotecan hydrochloride; Drug: oxaliplatin
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: cyclophosphamide; Drug: paclitaxel; Drug: pegylated liposomal doxorubicin hydrochloride; Other: placebo
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI); North Central Cancer Treatment Group; Cancer and Leukemia Group B
Recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Drug: docetaxel; Drug: goserelin; Drug: leuprolide acetate; Procedure: conventional surgery
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; NCIC Clinical Trials Group
Recruiting - verified March 2010
Condition: HIV Infections
Intervention: Drug: maraviroc
Sponsor: Pfizer
Recruiting - verified February 2010
Conditions: Breast Cancer; Metastatic Cancer
Intervention: Drug: dasatinib
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: capecitabine; Drug: cyclophosphamide; Drug: docetaxel; Drug: doxorubicin hydrochloride; Drug: gemcitabine hydrochloride; Procedure: conventional surgery
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Benign Prostatic Hyperplasia (BPH)
Intervention: Device: Prolieve® Thermodilatation System
Sponsor: Boston Scientific Corporation
Recruiting - verified February 2010
Condition: Breast Cancer
Interventions: Drug: fulvestrant; Drug: lapatinib ditosylate; Other: placebo
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Intervention: Drug: chemotherapy
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B
Recruiting - verified March 2010
Condition: Kidney Cancer
Interventions: Biological: bevacizumab; Drug: sorafenib tosylate; Drug: temsirolimus
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Osteoarthritis
Interventions: Drug: Celecoxib; Drug: Any commercially available NSAID with the indication for osteoarthritis
Sponsor: Pfizer
Recruiting - verified March 2010
Conditions: Heart Failure; Anemia; Cardiovascular Disease; Ventricular Dysfunction; Congestive Heart Failure
Interventions: Drug: Darbepoetin alfa; Drug: Placebo
Sponsor: Amgen
Recruiting - verified March 2010
Condition: Leukemia
Intervention: Drug: lenalidomide
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Kidney Cancer
Interventions: Drug: sorafenib tosylate; Drug: sunitinib malate; Other: placebo
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B; Southwest Oncology Group; NCIC Clinical Trials Group
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: docetaxel; Drug: gemcitabine hydrochloride; Drug: pemetrexed disodium; Drug: vinorelbine ditartrate
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; NCIC Clinical Trials Group; North Central Cancer Treatment Group
Recruiting - verified March 2010
Conditions: Leukemia; Myelodysplastic Syndromes
Interventions: Drug: azacitidine; Drug: entinostat
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: chemotherapy; Drug: exemestane; Drug: letrozole; Drug: tamoxifen citrate
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; American College of Surgeons; North Central Cancer Treatment Group; NCIC Clinical Trials Group; National Surgical Adjuvant Breast and Bowel Project (NSABP)
Recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Drug: antiandrogen therapy; Drug: docetaxel
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Colorectal Cancer
Interventions: Biological: bevacizumab; Biological: cetuximab; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: leucovorin calcium; Drug: oxaliplatin
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI); Southwest Oncology Group
Recruiting - verified March 2010
Condition: Colorectal Cancer
Interventions: Biological: bevacizumab; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin; Other: clinical observation
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Metastatic Cancer; Prostate Cancer
Interventions: Drug: atrasentan hydrochloride; Drug: docetaxel; Drug: prednisone; Other: placebo
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lymphoma
Interventions: Biological: filgrastim; Biological: rituximab; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: prednisone; Drug: vincristine sulfate
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Intervention: Procedure: quality-of-life assessment
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lymphoma
Interventions: Drug: cisplatin; Drug: etoposide; Drug: gemcitabine hydrochloride; Drug: methylprednisolone
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Intervention: Radiation: radiation therapy
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI); Radiation Therapy Oncology Group; Southwest Oncology Group
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Other: immunohistochemistry staining method; Procedure: conventional surgery
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Metastatic Cancer; Prostate Cancer
Interventions: Drug: zoledronic acid; Other: placebo
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI); Southwest Oncology Group; Eastern Cooperative Oncology Group; NCIC Clinical Trials Group
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: filgrastim; Biological: pegfilgrastim; Biological: trastuzumab; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Breast Cancer; Menopausal Symptoms; Sexual Dysfunction and Infertility
Interventions: Drug: cyclophosphamide; Drug: goserelin
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B; Eastern Cooperative Oncology Group; International Breast Cancer Study Group
Recruiting - verified March 2010
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Biological: filgrastim; Drug: cyclophosphamide; Drug: dexamethasone; Drug: melphalan; Drug: thalidomide; Procedure: peripheral blood stem cell transplantation
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Colorectal Cancer
Interventions: Drug: capecitabine; Drug: fluorouracil; Drug: oxaliplatin; Radiation: radiation therapy
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI); Cancer and Leukemia Group B
Recruiting - verified March 2010
Condition: Brain and Central Nervous System Tumors
Intervention: Drug: imatinib mesylate
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Drug: docetaxel; Drug: doxorubicin hydrochloride; Drug: estramustine phosphate sodium; Drug: ketoconazole; Drug: prednisone; Drug: vinblastine; Radiation: strontium chloride Sr 89
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified February 2010
Condition: Melanoma (Skin)
Interventions: Biological: recombinant interferon alfa; Other: clinical observation
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; NCIC Clinical Trials Group; Children's Oncology Group
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: letrozole; Other: placebo
Sponsors: NCIC Clinical Trials Group; National Cancer Institute (NCI); North Central Cancer Treatment Group; International Breast Cancer Study Group; Eastern Cooperative Oncology Group; Southwest Oncology Group; Cancer and Leukemia Group B; European Organization for Research and Treatment of Cancer
Recruiting - verified June 2009
All Locations ... United States » ... Montana » ... Missoula 
Login/sign up for more tools for finding clinical trials. Login/Sign up Here
